SPONSOR

Pfizer

Total Trials

Recruiting

Phases

Phase 2, Phase 1, Phase 3, Phase 1, Phase 2

Conditions studied: Asthma Healthy Volunteer Acromegaly Psoriatic Arthritis, Juvenile Polyarticular Juvenile Idiopathic Arthritis Chronic Leukemia Myelogenous Dermatomyositis Polymyositis Hidradenitis Suppurativa Advanced Breast Cancer

Pfizer is one of the largest biopharmaceutical companies in the world by research expenditure, with a clinical trial portfolio spanning oncology, rare diseases, vaccines, immunology, internal medicine, and neurology. Founded in 1849, Pfizer has brought more than 350 medicines and vaccines to patients globally, and today maintains one of the broadest Phase 2 and Phase 3 pipelines in the industry. Their clinical research operations span over 150 countries, making Pfizer trials accessible to a wide and diverse patient population.

Pfizer's oncology program — operating largely through its Pfizer Oncology unit — focuses on precision treatments including CDK4/6 inhibitors (palbociclib), EGFR-targeted therapies, antibody-drug conjugates, and immuno-oncology agents. Outside of cancer, Pfizer conducts extensive trials in cardiovascular and metabolic disease (including its ATTR cardiomyopathy drug tafamidis), rare pediatric conditions, and infectious disease. The COVID-19 mRNA vaccine program, conducted in partnership with BioNTech, included one of the largest Phase 3 vaccine trials in history with over 40,000 participants across six countries.

Participants in Pfizer-sponsored trials receive investigational treatments at no cost and are monitored by independent Data Safety Monitoring Boards. Pfizer trial sites are typically major academic medical centers, teaching hospitals, and specialist clinical research organizations. Eligibility criteria vary by study; most trials are listed on ClinicalTrials.gov with a direct contact link to the enrolling site.

Frequently Asked Questions — Pfizer

What therapeutic areas does Pfizer focus on in its clinical trials?

Pfizer's active clinical trial portfolio is concentrated across six primary therapeutic areas: oncology (including breast, lung, prostate, and hematologic cancers), rare diseases and gene therapy, vaccines and antivirals, internal medicine (heart failure, cardiomyopathy, metabolic disease), immunology and inflammation (rheumatoid arthritis, lupus, IBD), and neuroscience. Within oncology specifically, Pfizer runs a large number of Phase 1 and Phase 2 basket trials testing targeted agents across multiple tumor types simultaneously.

How are Pfizer clinical trial sites selected, and where are they located?

Pfizer selects trial sites based on investigator expertise, patient access, infrastructure capacity, and local regulatory readiness. The majority of Pfizer-sponsored trials operate across North America, Western Europe, and increasingly Asia-Pacific and Latin America to ensure diverse participant populations. In the United States, Pfizer frequently partners with NCI-designated cancer centers, major academic medical centers such as MD Anderson, Memorial Sloan Kettering, and Mayo Clinic, as well as community oncology networks. Site-level contact information for each trial is available on ClinicalTrials.gov.

Does participating in a Pfizer trial mean receiving an experimental drug?

Not necessarily. Many Pfizer trials include randomized controlled designs in which some participants receive the investigational treatment while others receive an active comparator (an approved standard-of-care therapy) or, in some cases, a placebo — always disclosed in the informed consent process. Participants never pay for investigational drugs, and in many trials receive study-related medical assessments at no cost. Pfizer trials are conducted under FDA and EMA oversight and follow ICH Good Clinical Practice guidelines.

Pfizer

Frequently Asked Questions — Pfizer

Clinical Trials by Pfizer

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants

Korean Regulatory Post Marketing Surveillance for Somavert

Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis

A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Post Marketing Surveillance(PMS) Study of Lorviqua in Korea

A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults.

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function